Neurocrine Biosciences Inc (NBIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurocrine Biosciences Inc (NBIX) has a cash flow conversion efficiency ratio of 0.119x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($388.40 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NBIX market cap overview for the company's overall valuation and market capitalisation.
Neurocrine Biosciences Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neurocrine Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurocrine Biosciences Inc ranked by their cash flow conversion efficiency. Explore NBIX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
COSCO Shipping Energy Transportation Co Ltd
SHG:600026
|
0.062x |
|
ICON PLC
NASDAQ:ICLR
|
0.030x |
|
Taiwan Cooperative Financial Holding Co Ltd
TW:5880
|
-0.080x |
|
Assurant, Inc.
NYSE:AIZ
|
0.075x |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
0.018x |
|
NESTE OYJ UNSP.ADR 1/2
F:NEFA
|
N/A |
|
Tbea Co Ltd
SHG:600089
|
0.014x |
|
Lennox International Inc
NYSE:LII
|
0.013x |
Annual Cash Flow Conversion Efficiency for Neurocrine Biosciences Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Neurocrine Biosciences Inc from 1996 to 2025. View latest Neurocrine Biosciences Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.25 Billion | $782.70 Million | 0.241x | +4.65% |
| 2024-12-31 | $2.59 Billion | $595.40 Million | 0.230x | +31.61% |
| 2023-12-31 | $2.23 Billion | $389.90 Million | 0.175x | -12.10% |
| 2022-12-31 | $1.71 Billion | $339.40 Million | 0.199x | +6.46% |
| 2021-12-31 | $1.37 Billion | $256.50 Million | 0.187x | -7.99% |
| 2020-12-31 | $1.13 Billion | $228.50 Million | 0.203x | -12.09% |
| 2019-12-31 | $636.90 Million | $147.00 Million | 0.231x | +9.43% |
| 2018-12-31 | $480.76 Million | $101.40 Million | 0.211x | +183.21% |
| 2017-12-31 | $372.14 Million | $-94.33 Million | -0.253x | +24.83% |
| 2016-12-31 | $314.88 Million | $-106.18 Million | -0.337x | -276.69% |
| 2015-12-31 | $424.45 Million | $-38.00 Million | -0.090x | +60.37% |
| 2014-12-31 | $208.70 Million | $-47.14 Million | -0.226x | +8.14% |
| 2013-12-31 | $120.41 Million | $-29.61 Million | -0.246x | -7.55% |
| 2012-12-31 | $154.37 Million | $-35.29 Million | -0.229x | -1867.95% |
| 2011-12-31 | $60.08 Million | $-698.00K | -0.012x | -100.45% |
| 2010-12-31 | $19.34 Million | $49.94 Million | 2.582x | +119.23% |
| 2009-12-31 | $3.95 Million | $-53.09 Million | -13.428x | -565.82% |
| 2008-12-31 | $36.77 Million | $-74.17 Million | -2.017x | -303.45% |
| 2007-12-31 | $118.70 Million | $-59.33 Million | -0.500x | -58.37% |
| 2006-12-31 | $314.72 Million | $-99.33 Million | -0.316x | -299.85% |
| 2005-12-31 | $390.10 Million | $-30.79 Million | -0.079x | +68.91% |
| 2004-12-31 | $393.83 Million | $-99.99 Million | -0.254x | -367.46% |
| 2003-12-31 | $391.12 Million | $37.13 Million | 0.095x | +126.82% |
| 2002-12-31 | $224.25 Million | $-79.36 Million | -0.354x | -402.61% |
| 2001-12-31 | $310.39 Million | $-21.86 Million | -0.070x | +38.36% |
| 2000-12-31 | $163.21 Million | $-18.64 Million | -0.114x | -6.92% |
| 1999-12-31 | $96.40 Million | $-10.30 Million | -0.107x | +28.10% |
| 1998-12-31 | $72.00 Million | $-10.70 Million | -0.149x | -212.40% |
| 1997-12-31 | $83.20 Million | $11.00 Million | 0.132x | +43.66% |
| 1996-12-31 | $72.80 Million | $6.70 Million | 0.092x | -- |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more